Literature DB >> 32901285

The win ratio approach for composite endpoints: practical guidance based on previous experience.

Björn Redfors1,2,3, John Gregson4, Aaron Crowley1, Thomas McAndrew1, Ori Ben-Yehuda1,2, Gregg W Stone1,5, Stuart J Pocock4.   

Abstract

The win ratio was introduced in 2012 as a new method for examining composite endpoints and has since been widely adopted in cardiovascular (CV) trials. Improving upon conventional methods for analysing composite endpoints, the win ratio accounts for relative priorities of the components and allows the components to be different types of outcomes. For example, the win ratio can combine the time to death with the number of occurrences of a non-fatal outcome such as CV-related hospitalizations (CVHs) in a single hierarchical composite endpoint. The win ratio can provide greater statistical power to detect and quantify a treatment difference by using all available information contained in the component outcomes. The win ratio can also incorporate quantitative outcomes such as exercise tests or quality-of-life scores. There is a need for more practical guidance on how best to design trials using the win ratio approach. This manuscript provides an overview of the principles behind the win ratio and provides insights into how to implement the win ratio in CV trial design and reporting, including how to determine trial size. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Clinical trials; Composite endpoints; Methods; Win ratio

Mesh:

Year:  2020        PMID: 32901285     DOI: 10.1093/eurheartj/ehaa665

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  1 in total

1.  Comparing Minimally Invasive and Open Pancreaticoduodenectomy for the Treatment of Pancreatic Cancer: a Win Ratio Analysis.

Authors:  Eliza W Beal; Djhenne Dalmacy; Alessandro Paro; J Madison Hyer; Jordan Cloyd; Mary Dillhoff; Aslam Ejaz; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2022-06-15       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.